Investing In Health Stocks - How Policy Clarity Is Opening Doors

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

Seeking Alpha • Nov 11, 2025

Global X Announces Five ETF Reverse Stock Splits

NEW YORK, Aug. 18, 2025 /PRNewswire/ -- Global X Management Company, LLC ("Global X"), the New York-based provider of exchange traded funds (ETFs), today announced reverse splits of the following five funds (each a "Fund" or collectively, "Funds")

PRNewsWire • Aug 18, 2025

Healthcare Sector Checkup As U.S. Looks To Change Regulations

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

Seeking Alpha • May 30, 2025

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?

Seeking Alpha • Feb 25, 2025

The 3 Best Gene Editing Stocks to Buy in July 2024

Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. With the technology, we can fix faulty genes, or replace them with healthier genes in an attempt to cure diseases or help the body fight disease.

InvestorPlace • Jul 8, 2024

Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life

Genomics is the future of medicine. With it, companies are racing to shed light on human health and disease.

InvestorPlace • May 10, 2024

3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire

Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion from $5.3 billion in 2023.

InvestorPlace • May 2, 2024

GNOM: Genomics Still Waiting For Its 'ChatGPT' Moment

GNMO invests across companies benefiting from advancements in the field of genomics within biotechnology. The fund's historical performance has been poor amid volatile stock prices for underlying holdings. Genomics may be the future, but still missing a blockbuster application to drive a wave of bullish momentum into the segment.

Seeking Alpha • Mar 22, 2024

3 Stocks That Could Be the Next Big Thing in Gene Editing

Gene editing could revolutionize how millions of patients are treated all over the world. That could create big opportunities for some of the most exciting gene-editing stocks.

InvestorPlace • Mar 21, 2024

3 Gene Editing Stocks With Unprecedented Surge Potential

Gene editing is revolutionizing medicine. For example, just weeks ago, the U.S. Federal Drug Administration approved a new gene-editing treatment for sickle cell disease and transfusion-dependent beta-thalassemia, a genetic disorder that prevents the production of hemoglobin in the blood and requires regular blood transfusions.

InvestorPlace • Feb 13, 2024